The “anaplastic lymphoma tyrosine kinase” receptor, ALK, is altered by gain-of-function point mutations in half of familial neuroblastoma cases (~ 1% of total cases), and in around 9% of sporadic neuroblastoma, climbing up to 14% in high-risk patients [11, 120–122]. This evidence concerns the gene ALK and neuroblastoma.